SCHEMBL2990952

SCHEMBL2990952

COc1cc2c(nc1OC)c(-c1cc3c(CNCCCN4CCN(C)CC4)ccnc3[nH]1)cn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.40
CD274 Q9NZQ7 1/20 0.37
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
CCNT1 O60563 9/20 0.34
CDK9 P50750 9/20 0.34
MEN1 O00255 1/20 0.34
RAD52 P43351 1/20 0.34
KMT2A Q03164 1/20 0.34
JAK2 O60674 1/20 0.34
LCK P06239 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
CDK7 P50613 1/20 0.34
BTK Q06187 1/20 0.34
LRRK2 Q5S007 1/20 0.34
DYRK3 O43781 1/20 0.33
CDK2 P24941 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993570 0.94 IGF1R (0.40) IGF1RAURKBCCNT1CDK9JAK2
SCHEMBL2990022 0.85 IGF1R (0.40) IGF1RCDK9DYRK3CDK2CLK1
SCHEMBL2995039 0.83 IGF1R (0.42) IGF1RAURKBCCNT1CDK9JAK2
SCHEMBL2986378 0.83 IGF1R (0.41) IGF1RAURKBCCNT1CDK9JAK2
SCHEMBL2996917 0.82 IGF1R (0.45) IGF1RAURKBAURKACCNT1CDK9
SCHEMBL2991640 0.81 IGF1R (0.40) IGF1RAURKBAURKACCNT1CDK9
SCHEMBL2986604 0.81 IGF1R (0.44) IGF1RAURKBCCNT1CDK9JAK2
SCHEMBL2985996 0.81 IGF1R (0.48) IGF1RAURKBAURKACCNT1CDK9
SCHEMBL2982560 0.81 IGF1R (0.48) IGF1RAURKBAURKACCNT1CDK9
SCHEMBL5529651 0.80 CCNT1 (0.43) IGF1RCCNT1CDK9GSK3BCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 IGF1R 606/4885CD274 3995/4885AURKB 186/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 IGF1R 606/4885CD274 3995/4885AURKB 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.